Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Research across Cancer
Related studies from across the Cancer family.
Delayed margin formation in lung tumor microwave ablation may occur despite lack of immediate intraprocedural margin
Microwave ablation of lung tumors may show delayed results
This case report describes a single patient with a metastatic lung tumor treated with CT-guided microwave ablation. A well-defined margin ap…
A lung tumor may not show immediate signs of treatment success, but a delayed response can still indicate the procedure worked.
Immunotherapy regimens for TKI-resistant NSCLC are not cost-effective without significant price reductions
New lung cancer treatments show better results but higher costs
This network meta-analysis evaluated the cost-effectiveness of three immunotherapy-based combinations compared to chemotherapy in patients w…
Newer drug combinations offer better survival for certain lung cancer patients, but high costs currently make them difficult to fund widely.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
EGFR and TP53 mutations linked to worse survival in sinonasal squamous cell carcinoma
Genetic markers linked to survival in sinonasal squamous cell carcinoma
A meta-analysis of 25 retrospective cohort studies including 1194 patients with sinonasal squamous cell carcinoma found that EGFR and TP53 m…
Specific genetic mutations and protein levels can help doctors predict how patients with certain head and neck cancers will respond to treat…
Diverse therapeutic approaches including immunotherapy are utilized for patients with occult squamous cell carcinoma
Men and women show different patterns in squamous cell carcinoma
This systematic review of case reports examines clinical characteristics and treatment strategies for patients with occult squamous cell car…
New data shows that men and women experience different locations for lymph node spread in certain types of skin cancer.
Actinic keratosis increases melanoma risk while alcohol consumption is associated with lower squamous cell carcinoma risk
Actinic Keratosis Linked to Higher Risk of Melanoma
This meta-analysis of genome-wide association studies evaluates causal relationships between 11 modifiable risk factors and skin cancers. Th…
New research identifies a link between actinic keratosis and melanoma risk while highlighting potential new targets for skin cancer treatmen…
Sugar sweetened beverages and orange juice are associated with increased risk of several cancer types
Sugar sweetened drinks may increase risk of several cancer types
This meta-analysis of 51 cohort studies evaluates the link between sugar sweetened beverages (SSBs), artificially sweetened beverages (ASBs)…
New research suggests a link between sugar-sweetened beverages and an increased risk of certain cancers, including pancreatic and colorectal…
EGFR inhibitors show reproducible activity and manageable toxicity in locally advanced or metastatic anal squamous cell carcinoma
EGFR Inhibitors Show Activity in Advanced Anal Squamous Cell Carcinoma
This meta-analysis of 404 patients evaluated EGFR inhibitors (cetuximab and panitumumab) for anal squamous cell carcinoma. The analysis foun…
New analysis shows that EGFR inhibitors like cetuximab and panitumumab may improve response rates for patients with advanced anal squamous c…
Serplulimab plus chemotherapy improves overall survival compared to chemotherapy alone in nsq-NSCLC
Trial shows serplulimab improves survival in certain lung cancers
This Phase III randomized controlled trial of 636 treatment-naïve patients with locally advanced or metastatic nsq-NSCLC found that serpluli…
A new clinical trial shows that adding serplulimab to chemotherapy can extend life for patients with specific types of non-small cell lung c…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Transitioning from static TNM staging to a multidimensional, adaptive treatment model integrating genomics and immunology for HPV-associated OPSCC
Doctors are shifting from static staging to adaptive care for HPV throat cancer
This narrative review discusses the evolving management of HPV-associated oropharyngeal squamous cell carcinoma. The authors argue for trans…
Medical teams are moving away from old staging rules toward a new model that uses genomics and immunology for precise care.